Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

G1 Therapeutics Inc (GTHX) USD0.0001

Sell:$21.20 Buy:$21.23 Change: $1.42 (7.18%)
NASDAQ:0.06%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$21.20
Buy:$21.23
Change: $1.42 (7.18%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$21.20
Buy:$21.23
Change: $1.42 (7.18%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Contact details

Address:
700 Park Offices Drive, Suite 200
RESEARCH TRIANGLE PARK
27709
United States
Telephone:
+1 (919) 2139835
Website:
www.g1therapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GTHX
ISIN:
US3621LQ1099
Market cap:
$812.86 million
Shares in issue:
37.74 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Garry Nicholson
    Independent Chairman of the Board
  • Mark Velleca
    President, Chief Executive Officer, Director
  • Jennifer Moses
    Chief Financial Officer
  • Terry Murdock
    Chief Operating Officer
  • Rajesh Malik
    Chief Medical Officer, Senior Vice President - Research and Development
  • Jay Strum
    Chief Scientific Officer
  • James Hanson
    General Counsel, Secretary
  • Mark Avagliano
    Chief Business Officer
  • Soma Gupta
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.